Physician profile
Ronald E Bugaoan
NPI 1861551236
$35,590.11
in general payments reported to CMS, 2019-2025
19 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,858 · 2021: $3,412 · 2022: $1,328 · 2023: $744 · 2024: $851 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21,985.85 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $10,653.61 | 2019-2025 | Sublocade |
| Abbvie INC. | $1,046.97 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.68 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $279.09 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $263.67 | 2023-2024 | Sunosi, Auvelity |
| Lundbeck LLC | $191.87 | 2021-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $183.02 | 2019-2025 | Fanapt |
| Corium, LLC | $171.12 | 2023-2025 | Azstarys |
| Braeburn INC. | $101.33 | 2023-2025 | Brixadi |
| Allergan, INC. | $85.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $82.65 | 2021-2022 | |
| Bausch Health US, LLC | $42.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $42.57 | 2019 | |
| Tempus Ai, INC | $36.43 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Masimo Corporation | $25.12 | 2021 | |
| Hikma Pharmaceuticals USA | $22.35 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.93 | 2019 | |
| Neurocrine Biosciences, INC. | $16.05 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bugaoan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.